glp 1 lilly Eli stock soars on encouraging results for daily weight-loss pill The Food and Drug Administration

Buford debunks some of the most common myths associated with GLP-1 agonists for weight loss

GLP-1 medications like Ozempic can lead to delayed or blunted effects from oral psychedelics like psilocybin or MDMA.

This state-of-the-art narrative review synthesizes current evidence from clinical trials, pharmacovigilance databases, and real-world cohorts to provide a comprehensive evaluation of the safety and tolerability of GLP-1RAs and tirzepatide

This guide explores prescription options, compounded alternatives, and how genetic and biomarker factors may inform provider conversations about suitability

Given the heterogeneity of the included evidencespanning case reports, pharmacovigilance analyses, and observational cohortsthis review is framed primarily as a signal-detection and evidence-mapping exercise rather than a causal-inference analysis